HighTower Advisors’s Axsome Therapeutics AXSM Stock Holding History

HighTower Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.8M	Sell	56,313 -320	-0.6%	-$69.4K	0.01%	794
2026 Q1	$9.57M	Buy	56,633 +661	+1%	+$114K	0.01%	901
2025 Q4	$10.2M	Sell	55,972 -1,143	-2%	-$160K	0.01%	856
2025 Q3	$6.94M	Buy	57,115 +46,153	+421%	+$5.2M	0.01%	1005
2025 Q2	$1.14M	Sell	10,962 -2,588	-19%	-$274K	﹤0.01%	1926
2025 Q1	$1.58M	Buy	13,550 +90	+0.7%	+$10.3K	﹤0.01%	1649
2024 Q4	$1.14M	Buy	+13,460	New	+$1.24M	﹤0.01%	1873
2023 Q3	–	Sell	-2,778	Closed	-$199K	–	3579
2023 Q2	$199K	Buy	+2,778	New	+$205K	﹤0.01%	2872
2023 Q1	–	Sell	-3,328	Closed	-$256K	–	3414
2022 Q4	$256K	Buy	+3,328	New	+$199K	﹤0.01%	2589

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HighTower Advisors's AXSM Position: Q2 2026 in Review

HighTower Advisors reduced its Axsome Therapeutics (AXSM) stake by 0.57% in Q2 2026, selling an estimated $69.4K and leaving 56,313 shares worth $13.8M. The position accounts for 0.01% of the portfolio, ranked #794.

HighTower Advisors first reported a position in AXSM in Q4 2022 and has held it in 9 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

HighTower Advisors held 56,313 shares of Axsome Therapeutics worth $13.8M as of Q2 2026.
HighTower Advisors sold 320 Axsome Therapeutics shares in Q2 2026, an estimated $69.4K.
Axsome Therapeutics made up 0.01% of HighTower Advisors's portfolio in Q2 2026, its #794 holding.
HighTower Advisors first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 9 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.